Abstract 4444
Background
Burn-Out Syndrome (BOS) in oncology nurses, has few experiences reported about its incidence and impact in its three different areas: emotional and physical exhaustion, cynism and despersonalization and no personal nor profesional fulfillment. There is a lack of resources for its diagnosis and management, although it impacts negatively in the patient attention/ care quality and the quality of institutional processes, added the personal impact in personal workers lives. Our objective was to determine the incidence of the BOS in our workers, analyze its causes and reduce in 20% the percentage of workers suffering or at risk of suffering BOS.
Methods
23 nurses / nurse assistants from Medical Oncology Department at University General Hospital of Valencia fulfilled an anomized questionnaire that included personal details, the GHQ-12 evaluation and the Maslach index questions; both at baseline and after each intervention. Causes of BOS were analysed, and process map and Ishikawa fish-bone scheme were designed. Interventions were carried in consequence. Data analyze through SPSS.
Results
23 subjects, 87% women, 47 years old median age. 15 at ward, 8 at clinic. 90% > 5 years in Oncology. At baseline, 75% GHQ-12 good health. Maslach index: 70%, 45% and 55% in risk (medium+high) of BOS related to exhaustion, despersonalization or fulfillment, respectively. In exhaustion, 35% medium risk, 35% high risk of BOS. Priority-matrix development, ergonomy tips and self-improvement tools identified as adequated interventions. After ergonomy tips intervention, 90% GHQ-12 good health, 15% exhaustion medium risk and 50% high risk; 65% at risk of BOS related to exhaustion. Improvement of 5% lowering risk of suffering BOS.
Conclusions
BOS is complex to measure due to answer subjetivity. We have healthier workers, but although levels of exhaustion have decreased, those who were already exhausted are worse than before. Possible causes: renovation work on the clinic, labor inestability, local holidays during evaluation. Self-improvement tools sessions are now being held to reduce risk ot BOS. Reevaluation of activity will be definitory of its success.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract